The Use of H1 and H2 Histamine Antagonists with Morphine Anesthesia: A Double-Blind Study

Philbin, Daniel M.; Moss, Jonathan; Akins, Cary W.; Rosow, Carl E.; Kono, Katsuakira; Schneider, R.; VerLee, T.; Savarese, John J.; Owens, William D.

doi:10.1097/00132586-198206000-00032

Cited by 23 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Before reliable and practicable [20] histamine assays in human plasma became available for routine use [4,26,27] a histamine-release response to drugs could not be estimated in clinical conditions with an acceptable accuracy [9,10,28,29,34,36,45,51,58,62]. But even one decade after the discovery of H2-receptor antagonists [5] and the development of these highly sensitive and specific asays [4,26] histamine was still not generally recognized as an important mediator of any pathological and clinical phenomenon [63].…”

Section: Introductionmentioning

confidence: 99%

Definition and classification of the histamine-release response to drugs in anaesthesia and surgery: Studies in the conscious human subject

Doenicke²,

et al. 1982

View full text Add to dashboard Cite

Summary. In 2 clinical studies in 40 conscious human volunteers and 164 orthopedic patients histamine-release responses were diagnosed, defined and classified. Polygeline (Haemaccel) in its now outdated formulation [40] was chosen as a clinical histamine releaser. The main interest was not concentrated on the extreme, the "classical" anaphylactic response, but on the average histamine-release response found in clinical experiments with so many drugs in the last 10 years.In human volunteers 600 ng/kg histamine was i.v. injected. Indicants for a systemic anaphylactoid reaction with the highest incidence ratio were tachycardia, plasma histamine levels > t ng/ml, "metallic taste", flush, congestion of head, "wet eyes" and tears, hypertension and headache. Following polygeline none of these subjects developed a life-threatening reaction, but 12 showed a systemic response, 11 a cutaneous reaction and 17 were non-responders. Indieants for a systemic anaphylactoid reaction with the highest incidence ratio were plasma histamine levels > 1 ng/ml, tachycardia, wheals, sensation of heat, narrowness of throat, hypertension, headache and wet eyes or tears.In a prolective, cohort study in the orthopedic patients 3 subjects with life-threatening reactions, 27 with systemic response, 96 with cutaneous reaction and 38 non-responders were included. Indicants with the highest incidence ratio were tachycardia, plasma histamine levels > 1 ng/ml, erythema and wheals, cough, flush, stuffy nose and facial oedema. With this trial the indicants for diagnosing a systemic histamine release response in volunteers were validated in patients to a large extent.Thus the average histamine-release response was defined by clinical signs such as tachycardia and mild hypertension, scattered hives such as spots of erythema and wheals, respiratory symptoms in the laryngeal and nasal region, such as cough, narrowness in the throat, stuff), nose and sneezing and by pathological plasma histamine levels (> 1 ng/ml), in addition histamine-release responses were differentiated as cutaneous responses, systemic responses and life-threatening responses by clinical and operational criteria and by plasma histamine levels. Using clinical trials and medical * Dedicated to Professor Otto Lindenschmidtt ** Supported by grant of Deutsche Forschungsgemeinschafl (Lo 199/10 and Lo 199/13-6) Offprint requests to: Professor Dr. W. Lorenz (address see above) decision making procedures the incidence of systemic histamine-release responses in patients higher by two orders of magnitude than in other studies reported hitherto.

show abstract

Section: Introductionmentioning

confidence: 99%

Definition and classification of the histamine-release response to drugs in anaesthesia and surgery: Studies in the conscious human subject

Doenicke²,

et al. 1982

View full text Add to dashboard Cite

show abstract

“…Other studies with Cetirizine and ranitidine, diphenhydramine and ranitidine, terfenadine and ranitidine showed similar results [7,8]. It has been observed that the H1 antagonist-H2 antagonist combination inhibits the release of allergic mediators, whether IgE dependent or otherwise [9][10][11]. However, antihistamines are only partially effective in inhibiting wheal formation in some chronic Urticaria patients; hence it is very probable that other mediators apart from histamine may play a role in wheal formation in chronic Urticaria [12,13].…”

Section: Open Accessmentioning

confidence: 82%

Efficacy of Montelukast and Ranitidine as an Add on Therapy for Chronic Urticaria

S¹,

Dinesh²

2018

IJCPT

View full text Add to dashboard Cite

“…H 1 -receptors facilitate preformed histamine release and are also involved in changes in capillary permeability [52]. In addition, H 1 -receptors interact with H 2 -receptors during vasodilation, prompting a recommendation that H 1 and H 2 -receptor antagonists be given together as prophylaxis [3,15,26,[52][53][54]. Glucocorticoids, as anti-inflammatories and mast cell stabilizers, are recommended in specific circumstances, for example anesthesia and surgery, or the rare case of recurrent cardiovascular collapse [12,15,27,30].…”

Section: Preoperative Preparationmentioning

confidence: 99%

“…With the exception of sufentanil, it has not yet been claimed that commonly used anesthesia drugs are associated with serious perioperative outcomes for children with known preexisting disease [45] (Table 2). Theoretically, narcotic-related and muscle relaxantrelated histamine release can be minimized by use of newer generation drugs of high potency (requiring less drug) and slow administration [1,4,53,[58][59][60]]. An inverse relationship has been noted between narcotic potency and the tendency to induce histamine release.…”

Section: Intraoperative Managementmentioning

confidence: 99%

Anesthetic considerations in pediatric mastocytosis: a review

Klein

Misseldine

2013

J Anesth

View full text Add to dashboard Cite

Mastocytosis is an orphan disease rarely encountered by practicing anesthesiologists. Children with mastocytosis often present for procedures or surgery requiring anesthesia. Because many of the medications commonly used in pediatric anesthesia have been reported to initiate mast cell activation, parents are often very anxious about their child's perioperative experience. Laboratory investigations of serum histamine assays associated with different anesthetic drugs have not been shown to predict mast cell degranulation in these patients. However, the pediatric literature suggests that children with disease limited to the skin rarely suffer serious side effects from anesthesia, and there are no reported fatalities. Preoperative prophylaxis is usually based on expert opinion and case reports. Detailed tables summarizing reports of anesthetic medications used for children with mastocytosis undergoing anesthesia, reported side effects, and suggested prophylaxis regimens are included in this review.

show abstract

The Use of H1 and H2 Histamine Antagonists with Morphine Anesthesia: A Double-Blind Study

Cited by 23 publications

References 0 publications

Definition and classification of the histamine-release response to drugs in anaesthesia and surgery: Studies in the conscious human subject

Definition and classification of the histamine-release response to drugs in anaesthesia and surgery: Studies in the conscious human subject

Efficacy of Montelukast and Ranitidine as an Add on Therapy for Chronic Urticaria

Anesthetic considerations in pediatric mastocytosis: a review

Contact Info

Product

Resources

About